http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Nitroblue tetrazolium test를 이용한 소아백혈구의 임상실험
김순겸 고려대학교 의과대학 1980 고려대 의대 잡지 Vol.17 No.2
Nitroblus tetrazolium dye reduction test has been widely used cytochemically which can be reduced to water insoluble formazan by neutrophils during phagocytosis. The slightly modified cytochemical NBT test to Gifford and Malawista was performed in 140 cases with healthy normal children and various infectious diseases to determine whether this NBT test would be of diagnostic value in patients having infectious diseases. The followings were obtained as results. 1) The mean ±SD of NBT positive neutrophils was 31.5±11.7% in healthy control group and no differences were observed between NBT test without latex particles and the test with latex particls. 2) In newborn infants the percentage of NBT positive neutrophils was initially increased on the first day of life, decreasing gradually day by after birth. 3) The percentage of NBT positive neutrophils was highly increased in bacterial infections, however in viral infections and tuberculosis the results of the test were in normal range. 4) Bacterial endotoxin stimulated NBT reduction by actin in first incubation and stercid did not depress the formazan cell count in vitro.
Kim, Jee Hung,Park, Hyung Soon,Heo, Su Jin,Kim, Sang Kyum,Han, Jung Woo,Shin, Kyoo-Ho,Kim, Seung Hyun,Hur, Hyuk,Kim, Kyung Sik,Choi, Young Deuk,Kim, Sunghoon,Lee, Young Han,Suh, Jin-Suck,Ahn, Joong-Ba S. Karger AG 2019 Oncology Vol.96 No.2
<P><B><I>Background:</I></B> We retrospectively investigated the treatment outcomes of second-line treatment with pazopanib or gemcitabine/docetaxel in patients with advanced soft tissue sarcoma (STS). <B><I>Methods:</I></B> Ninety-one patients who were treated with pazopanib or gemcitabine/docetaxel for advanced STS between 1995 and 2015 were analyzed. <B><I>Results:</I></B> Forty-six and 45 patients received pazopanib and gemcitabine/docetaxel, respectively. The median progression-free survival for the group treated with pazopanib was 4.5 months compared with 3.0 months for the gemcitabine/docetaxel group (<I>p</I> = 0.593). The median overall survival for the group treated with pazopanib was 12.6 months compared with 14.2 months for the gemcitabine/docetaxel group (<I>p</I> = 0.362). The overall response rates (ORRs) were 6.5 and 26.7% in the pazopanib and gemcitabine/docetaxel groups, respectively. The following parameters had ORRs favoring gemcitabine/docetaxel: age ≥50 years (31.6 vs. 2.9%, <I>p</I> = 0.006), histologic grade 1–2 (40.9 vs. 0%, <I>p</I> = 0.001), and poor first-line treatment response (23.3 vs. 3.0%, <I>p</I> = 0.022). Gemcitabine/docetaxel was associated with better ORRs for the following histologic subtypes: leiomyosarcoma (<I>p</I> = 0.624), malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma (<I>p</I> = 0.055), and angiosarcoma (<I>p</I> = 0.182). However, the ORR of synovial sarcoma favored pazopanib (<I>p</I> = 0.99). <B><I>Conclusions:</I></B> The efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments after doxorubicin or ifosfamide failure differed among clinical and histologic subgroups and appeared to facilitate a more personalized treatment approach for advanced STS.</P>
Kim, Dong-Uk,Seong, Chi-Nam,Jahng, Kwangyeop,Lee, Soon Dong,Cha, Chang-Jun,Joh, Kiseong,Jeon, Che Ok,Kim, Seung-Bum,Kim, Myung Kyum The National Institute of Biological Resources 2018 Journal of species research Vol.7 No.2
In 2016, as a subset study to discover indigenous prokaryotic species in Korea, a total of 15 bacterial strains were isolated and assigned to the class Betaproteobacteria. From the high 16S rRNA gene sequence similarity (>98.8%) and formation of a robust phylogenetic clade with the closest species, it was determined that each strain belonged to each independent and predefined bacterial species. There is no official report that these 15 species have been described in Korea; therefore, 1 strain of the Aquitalea, 5 strains of the Paraburkholderia, 2 strains of the Comamonas, 1 strain of the Cupriavidus, 1 strain of the Diaphorobacter, 2 strains of the Hydrogenophaga, 1 strain of the Iodobacter, 1 strain of the Massilia and 1 strain of the Rhodoferax within the Betaproteobacteria are described for unreported bacterial species in Korea. Gram reaction, colony and cell morphology, basic biochemical characteristics, and isolation sources are also described in the species description section.
Unrecorded prokaryotic species belonging to the class Actinobacteria in Korea
Kim, Mi-Sun,Jeong, Seong-Hwa,Kang, Joo-Won,Kim, Seung-Bum,Cho, Jang-Cheon,Cha, Chang-Jun,Im, Wan-Taek,Bae, Jin-Woo,Lee, Soon-Dong,Kim, Won-Yong,Kim, Myung-Kyum,Seong, Chi-Nam The National Institute of Biological Resources 2019 Journal of species research Vol.8 No.1
For the collection of indigenous prokaryotic species in Korea, 35 strains within the class Actinobacteria were isolated from various environmental samples (animals and clinical specimens) in 2017. Each strain showed high 16S rRNA gene sequence similarity (>98.8%) and formed a robust clade with recognized actinobacterial species. The isolates were assigned to 35 species, 22 genera, 15 families, and 8 orders of the class Actinobacteria. There are no official descriptions of these 35 bacterial species in Korea. Morphological properties, basic biochemical characteristics, isolation source, and strain IDs are included in the species descriptions.